Delivered intrathecally to SOD1 familial ALS patients, an AON against SOD1 was well tolerated in early trials [87] but it was recently announced that Tofersen did not meet its primary efficacy endpoint in a phase III trial, though reduced disease progression was apparent in secondary and exploratory endpoints. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.